Drug Makers Urge Caution In Thai Review Of Compulsory License Policy
This article was originally published in PharmAsia News
Drug makers are urging Thailand's new government to proceed with caution in deciding whether to keep a compulsory license policy for drugs. The Thai Chamber of Commerce fears that if the CL policy continues, the country could end up on the U.S. list of countries denied favorable trade treatment. The urging coincided with the new prime minister's instructions to the ministries of Public Health, Commerce and Foreign to consider the matter. (Click here for more
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.